A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)

Trial Profile

A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Human papillomavirus infections; Vulvovaginal cancer
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 04 Nov 2013 Final safety and efficacy data from an immunobridging phase III trial in Human papilloma virus infections presented at the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) Congress, according to a Merck media release.
    • 20 Mar 2012 This trial has been recruiting in Belgium and Spain.
    • 22 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top